For loco-regional advanced head and neck squamous cell carcinoma, concomitant radiotherapy with anti-EGFR target therapy such as Cetuximab (C225, ErbituxTM) has been shown to improve locoregional control and reduce mortality [20]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.